AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12439787
Drug: Estradiol 2
RxNorm normalized name: estradiol 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol 2 mg continued for another nine months with medroxyprogesterone for ten days every three months
Trial: 10080612
Drug: Topotecan (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan (1.5 mg/m2, 30-minute infusion daily for 5 days every 21 days)
Trial: 10080612
Drug: CAV (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAV (cyclophosphamide 1,000 mg/m2, doxorubicin 45 mg/m2, vincristine 2 mg, infused on day 1 every 21 days)
Trial: 2248508
Drug: Cyclophosphamide for
RxNorm normalized name: Cyclophosphamide for Injection
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide for eight weeks (2 mg/kg/day)
Trial: 2248508
Drug: Cyclophosphamide for
RxNorm normalized name: Cyclophosphamide for Injection
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide for twelve weeks (2 mg/kg/day)
Trial: 31847536
Drug: Varenicline (smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (smoking cessation treatment)
Trial: 28105737
Drug: Twice-daily tooth
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily tooth brushing with a rotating-oscillating power toothbrush (Oral-B Professional Care 1000™)
Trial: 23466649
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate (TDF), 300 mg orally per day
Trial: 15682845
Drug: Intravenous regional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous regional blockade therapy consisting of dexamethasone and lidocaine
Trial: 9582556
Drug: Oral daily
RxNorm normalized name: Summer's Eve Sheer Floral Daily Cloths
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral daily calcitriol 0.5 micrograms/die (Treatment A)
Trial: 9582556
Drug: Three oral
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three oral boluses of 2 micrograms of calcitriol a week (Treatment B)
Trial: 9582556
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral bolus of 2 micrograms of calcitriol a week (Treatment C)
Trial: 9582556
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (15 patients, mean age 47 +/- 12 years, creatinine clearances of 21 +/- 12 ml/min)
Trial: 7812699
Drug: Immunoscintigraphy (IS)
RxNorm normalized name: IS-5MN
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immunoscintigraphy (IS) using iodine‐131 anti‐carcinoembryonic antigen (CEA) and anti‐carbohydrate 19‐9 (CA 19-9) monoclonal antibody
Trial: 30845365
Drug: Alendronic acid
RxNorm normalized name: Alendronic Acid
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronic acid 70 mg once weekly (n=215)
Trial: 30427494
Drug: 40% mangosteen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40% mangosteen peel extract gel (MP-40)
Trial: 30427494
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (negative-control)
Trial: 30427494
Drug: Bleaching +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleaching + no treatment (positive-control)
Trial: 30427494
Drug: 10% mangosteen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% mangosteen peel extract gel (MP-10)
Trial: 30427494
Drug: 20% mangosteen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% mangosteen peel extract gel (MP-20)
Trial: 3045027
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of cisapride i.v.
Trial: 28853979
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg/day for 6 months
Trial: 21091877
Drug: Duloxetine 60-120
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60-120 mg/day for up to 34 weeks
Trial: 16267603
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg in the morning, placebo at bedtime
Trial: 16267603
Drug: Amitriptyline 25
RxNorm normalized name: amitriptyline 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 25 mg at bedtime, placebo in the morning
Trial: 16267603
Drug: Placebo (glucose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (glucose) in the morning, amitriptyline 25 mg at bedtime
Trial: 3304951
Drug: Cyclandelate at
RxNorm normalized name: Cyclandelate
DrugBank: Cyclandelate (DB04838)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclandelate at a dosage of 1600 mg/day
Trial: 24035327
Drug: Concurrent chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiation (CCRT) with fluorouracil (5‐FU) plus mitomycin
Trial: 21346001
Drug: Dopamine agonist
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine agonist pergolide given orally
Trial: 11220553
Drug: Sibutramine (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine (initial dosage of 5 mg/day titrated up by 5 mg biweekly through week 6, maintained at 20 mg through week 24)
Trial: 9123738
Drug: Neoadjuvant combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant combination therapy with flutamide and LHRH agonist for 3 months before radical prostatectomy
Trial: 8473453
Drug: Levonorgestrel (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel (0.75 mg for two doses 12 h apart)
Trial: 27245783
Drug: Intratympanic lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratympanic lidocaine and dexamethasone (ITLD) injection
Trial: 27245783
Drug: Intratympanic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratympanic saline injection (Control)
Trial: 24723218
Drug: Group art
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group art therapy
Trial: 22745140
Drug: Curcuminoid (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuminoid (30 mg 3 times daily)
Trial: 22745140
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium (25 mg 3 times daily)
Trial: 31099215
Drug: Electroacupuncture nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture nerve stimulation therapy (ENST), 50 min per session, three times a week for 3 months
Trial: 31099215
Drug: Perfusion therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perfusion therapy of four‐medication combination (heparin sodium, lidocaine, sodium bicarbonate, gentamicin sulfate), twice a week for the first 6‐8 weeks, then twice per month for 3 months
Trial: 28530451
Drug: High-Volume Injection
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Volume Injection (HVI)
Trial: 22348468
Drug: DHA-enriched fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-enriched fish oil supplement (250 mg DHA/d and 60 mg EPA/d)
Trial: 17629042
Drug: Infliximab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (5 mg/kg) at 0, 2, and 6 weeks, then every 8 weeks
Trial: 17629042
Drug: Methylprednisolone (0.8-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (0.8-1 mg/kg daily for 3 weeks, then tapering)
Trial: 11904593
Drug: Self-sampling methods
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-sampling methods (2 sequential swabs)
Trial: 10935831
Drug: Reduced glutathione
RxNorm normalized name: Reduced glutathione
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced glutathione (GSH) 600 mg intramuscularly for 12 weeks
Trial: 10935831
Drug: Symptomatic therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic therapies for 12 weeks
Trial: 2021388
Drug: High-dose intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intramuscular triamcinolone (360 mg over the first three days)
Trial: 2021388
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral prednisone (median dose 12.5 mg per day)
Trial: 2021388
Drug: High-dose intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intramuscular triamcinolone
Trial: 6302831
Drug: pivmecillinam 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pivmecillinam 200 mg t.i.d. for 1 week
Trial: 31806543
Drug: Denosumab (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (120 mg) subcutaneously every 3-4 weeks for about 6 months, then every 12 weeks for a total duration of 5 years.
Trial: 26634615
Drug: ICG-guided antihypertensive
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICG-guided antihypertensive therapy
Trial: 26634615
Drug: Empiric antihypertensive
RxNorm normalized name: aspirin / codeine phosphate Oral Tablet [Empirin with Codeine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empiric antihypertensive therapy
Trial: 22005661
Drug: Subepineural injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subepineural injection at the neural bifurcation
Trial: 22005661
Drug: Separate postbifurcation
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate postbifurcation injections around the tibial and peroneal nerves
Trial: 19126874
Drug: Resistant maltodextrin
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistant maltodextrin (RMD) 6 g in drinks
Trial: 19126874
Drug: Resistant maltodextrin
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistant maltodextrin (RMD) 6 g in solid foods
Trial: 7625347
Drug: Standard-phosphorus (215
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-phosphorus (215 micrograms/kJ, or 90 mg/100 kcal)
Trial: 7625347
Drug: Moderate-phosphorus (254
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-phosphorus (254 micrograms/kJ, or 106 mg/100 kcal)
Trial: 7625347
Drug: High-phosphorus (287
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-phosphorus (287 micrograms/kJ, or 120 mg/100 kcal)
Trial: 28912116
Drug: Tablet-based EORTC
RxNorm normalized name: BAKING POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based EORTC QLQ-C30 questionnaire
Trial: 22000938
Drug: Overall (across
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall (across medication phases)
Trial: 2229897
Drug: Punctum plug
RxNorm normalized name: Hippeastrum puniceum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Punctum plug treatment on one side
Trial: 28285255
Drug: 8h time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8h time in bed (TIB) restriction with fluoxetine 20-40 mg
Trial: 28285255
Drug: 6h time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6h time in bed (TIB) restriction with fluoxetine 20-40 mg
Trial: 25417042
Drug: Inspiratory muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory muscle training (IMT) using a pressure threshold device, 5 sessions weekly for 12 weeks, 30 mins/day
Trial: 16942534
Drug: Sildenafil (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (100 mg) vs Tadalafil (20 mg)
Trial: 16942534
Drug: Vardenafil (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil (20 mg) vs Tadalafil (20 mg)
Trial: 16942534
Drug: Tadalafil (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (20 mg) vs Sildenafil (100 mg)
Trial: 9327830
Drug: Antiplatelet drugs
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet drugs (aspirin, ticlopidine, thromboxane A2 receptor inhibitors)
Trial: 9327830
Drug: Antithrombotics (heparin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotics (heparin, hirudin, hirulog)
Trial: 9327830
Drug: ACE inhibitors,
RxNorm normalized name: ACE INHIBITORS, PLAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors, HMG‐CoA reductase inhibitors, fish‐oil supplements
Trial: 9327830
Drug: Glycoprotein IIb/IIIa
RxNorm normalized name: GLYCOPROTEIN IIB/IIIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycoprotein IIb/IIIa receptor antagonists, inhibitors of the early coagulation cascade, calcium channel blockers, nitric oxide donors
Trial: 18548088
Drug: Relaxation therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation therapies
Trial: 10099724
Drug: Portable liquid
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Portable liquid oxygen therapy (PLOT)
Trial: 1879247
Drug: Colloidal aqueous
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal aqueous solution of vitamin E (acetate ester)
Trial: 1879247
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil solution of vitamin E
Trial: 7092487
Drug: Repeated MAO-inhibitor
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated MAO-inhibitor treatment (crossover study of clorgyline and pargyline)
Trial: 24957712
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy treatment for neck pain
Trial: 9847269
Drug: Placebo arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo arm of the preventive therapy study
Trial: 8018457
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II infusion (1 ng min‐1 kg‐1)
Trial: 3698464
Drug: Indomethacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (200 mg)
Trial: 8018457
Drug: Indomethacin pre‐treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin pre‐treatment followed by angiotensin II infusion
Trial: 8018457
Drug: Frusemide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide (20 mg) administration
Trial: 2529659
Drug: Silicone gel
RxNorm normalized name: SILTREX Silicone Gel-Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone gel sheeting applied for 8 weeks (at least 12 hours a day)
Trial: 10490109
Drug: Silicone gel
RxNorm normalized name: SILTREX Silicone Gel-Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone gel sheeting
Trial: 26490109
Drug: Usual physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual physical therapy (comparator group)
Trial: 18603026
Drug: Acetazolamide 250
RxNorm normalized name: acetazolamide 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide 250 mg/day
Trial: 18603026
Drug: Acetazolamide 500
RxNorm normalized name: acetazolamide 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide 500 mg/day
Trial: 8196151
Drug: Pravastatin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (5 mg or 10 mg twice a day)
Trial: 30535670
Drug: PR-fampridine 10
RxNorm normalized name: amifampridine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PR-fampridine 10 mg twice daily
Trial: 28973344
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (20 ppm decreased to 10 ppm between 72 and 96 hours, then to 5 ppm until completion of therapy for 24 days)
Trial: 21556911
Drug: Protocol D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol D (saline chaser at 8 mL/s)
Trial: 21556911
Drug: Protocol C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol C (saline chaser at 4 mL/s)
Trial: 18482014
Drug: RCAC (1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCAC (1% formulation applied twice a day for 28 days)
Trial: 18482014
Drug: Placebo (applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (applied twice a day for 28 days)
Trial: 18482014
Drug: RCAC (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCAC (in vitro treatment)
Trial: 17130317
Drug: Sequential pneumatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential pneumatic leg pump therapy postoperatively
Trial: 17130317
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no pneumatic leg pump therapy)
Trial: 8928893
Drug: Double pharmacological
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double pharmacological autonomic blockade with propranolol (0.2 mg/kg iv) and atropine (0.04 mg/kg iv)
Trial: 1471411
Drug: B subunit‐whole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B subunit‐whole cell vaccine (B‐WC)
Trial: 6375258
Drug: Naloxone (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.4 and 2.0 mg)
Trial: 27658218
Drug: Cognitive-behavior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavior therapy (CBT) plus medication (zolpidem)
Trial: 27658218
Drug: CBT and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT and intermittent medication (prn)
Trial: 27658218
Drug: CBT without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CBT without additional treatment
Trial: 22475857
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses PENTA, then Dose 4 DTaP and Hib
Trial: 22475857
Drug: 4 QUAD
RxNorm normalized name: influenza virus vaccine 2023-2024 Quadrivalent Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 QUAD doses and Hib
Trial: 22475857
Drug: 4 PENTA
RxNorm normalized name: Pentam
DrugBank: Pentamidine (DB00738)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 PENTA doses
Trial: 22475857
Drug: Control vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control vaccine group (3 doses DTaP, IPV, and Hib and at Dose 4 DTaP and Hib)
Trial: 17084512
Drug: Arm A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm A: vinblastine (0.2 mg/kg on day 1), etoposide (100 mg/m2/d on days 1-5), cisplatin (40 mg/m2/d on days 1-5), and bleomycin (30 mg on days 1, 8, and 15)
Trial: 17084512
Drug: Arm B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm B: etoposide (350 mg/m2/d on days 1-5), cisplatin (40 mg/m2/d on days 1-5), and cyclophosphamide (1600 mg/m2/d on days 2-5)
Trial: 10073421
Drug: Lithium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium treatment (61 to 240 mo)
Trial: 10073421
Drug: Lithium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium treatment (0.7 to 6 mo)
Trial: 7675967
Drug: (+)-fenfluramine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (+)-fenfluramine (30 mg po)
Trial: 2105409
Drug: Formaldehyde vapor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formaldehyde vapor exposure at levels of 0.85 mg/m3, 0.12 mg/m3, and 0.008 mg/m3 for 90 min
Trial: 6255005
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogen (1.2-2.5 mg/day)
Trial: 31836196
Drug: Irbesartan (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (150 mg, increased to 300 mg as tolerated)
Trial: 30231896
Drug: Low-dose subcutaneous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose subcutaneous (SC) 300 mg crenezumab every 2 weeks for 68 weeks
Trial: 30231896
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous (IV) 15 mg/kg crenezumab every 4 weeks for 68 weeks
Trial: 27431341
Drug: Psychoeducation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducation with problem-solving (PEPS) therapy plus usual treatment
Trial: 24162943
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment alone
Trial: 27431341
Drug: Psychoeducation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducation with problem-solving (PEPS) therapy
Trial: 25514875
Drug: Placebo therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapy (Group D: 0 Joules)
Trial: 17453860
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg 17beta‐estradiol + 0.1 mg NETA